Delving into the Latest Updates on LC-200 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEye Diseases+ [2]

Active Indication

Lupus Erythematosus, DiscoidMultiple SclerosisOptic Neuritis+ [1]

Inactive Indication-

Originator Organization

Lipocure Ltd.

Active Organization

Lipocure Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

This study determined the effects of three dietary fibers namely, VITACEL LC200 powdered cellulose (LC200), barley beta-glucan concentrate (BBC), and VITACEL KF500 potato fiber (KF500), on the techno-functional and sensory properties and quality characteristics of Tunisian beef sausage. The findings revealed interesting functional properties for LC200 fiber. This fiber displayed high water binding capacity (WBC) and oil binding capacity (OBC), values of 16.2 g/g and 10.2 g/g, respectively, which are higher than reported for most fruit and vegetable fiber concentrates. The application of LC200 improved the masticability and elasticity of beef sausage formulations and minimized their hardness and production costs without negatively affecting their sensory properties. Overall, the findings demonstrate the potential functional and economic utility of LC200 fiber as a promising source of dietary fiber.

100 Deals associated with LC-200

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lupus Erythematosus, Discoid	Preclinical	IL	Lipocure Ltd.	09 Feb 2022
Multiple Sclerosis	Preclinical	IL	Lipocure Ltd.	09 Feb 2022
Optic Neuritis	Preclinical	IL	Lipocure Ltd.	09 Feb 2022
Rheumatoid Arthritis	Preclinical	IL	Lipocure Ltd.	09 Feb 2022